Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Amortizatization of Intangibles: 2018-2024

Historic Amortizatization of Intangibles for Intellia Therapeutics (NTLA) over the last 7 years, with Dec 2024 value amounting to $17.8 million.

  • Intellia Therapeutics' Amortizatization of Intangibles fell 74.66% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 57.93%. This contributed to the annual value of $17.8 million for FY2024, which is 31.20% down from last year.
  • Per Intellia Therapeutics' latest filing, its Amortizatization of Intangibles stood at $17.8 million for FY2024, which was down 31.20% from $25.9 million recorded in FY2023.
  • Intellia Therapeutics' Amortizatization of Intangibles' 5-year high stood at $25.9 million during FY2023, with a 5-year trough of -$7.6 million in FY2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $17.8 million (2024), whereas its average is $13.2 million.
  • In the last 5 years, Intellia Therapeutics' Amortizatization of Intangibles slumped by 1,313.38% in 2021 and then surged by 746.94% in 2023.
  • Intellia Therapeutics' Amortizatization of Intangibles (Yearly) stood at -$538,000 in 2020, then plummeted by 1,313.38% to -$7.6 million in 2021, then surged by 47.36% to -$4.0 million in 2022, then skyrocketed by 746.94% to $25.9 million in 2023, then crashed by 31.20% to $17.8 million in 2024.